

A stylized illustration of a human lung in shades of blue and white. A magnifying glass with a black handle and frame is positioned over the lower part of the lung, focusing on a detailed view of the bronchial tree. The background is white with scattered blue circles of various sizes. The bottom of the image features a solid blue horizontal bar.

GO₂ FOUNDATION
FOR LUNG CANCER

THE

Magnifying LeNS

LEARNING
NEW SCIENCE
QUARTERLY

JANUARY 2022

Navigating Biomarker Testing Issues



Due to the increasing number of approved targeted therapies for the treatment of lung cancer, clinical guidelines recommend that every patient receive comprehensive biomarker testing. Despite the importance of comprehensive biomarker testing, some people with lung cancer can face barriers that make it difficult to either obtain appropriate testing, or use the results of their testing to make informed treatment decisions.

[READ MORE](#)

Small Cell Lung Cancer Initiative 2021 Recap and Future Directions



Amy Kampschroeder, MA, OTR/L, CHES
Manager, Patient Outreach & Special Initiatives

In 2021, one of GO2 Foundation's priorities continued to be bringing lung cancer education and empowerment to patients to help ensure equitable healthcare. One of the tools GO2 Foundation used and continues to implement is the Small Cell Lung Cancer Initiative in which the overarching objective is to educate, support, and engage those affected by SCLC in an ongoing and consistent manner, and to bridge gaps in care and meet needs through outreach and authentic listening, expanding resources, and building community.

[READ MORE](#)

FDA Approvals: New Treatment Landscape in 2022



Despite 2021 being another challenging year, we saw treatment options for lung cancer increase by leaps and bounds. In 2021 the treatment landscape for lung cancer evolved to provide breakthrough treatment options targeting mutations that were previously unavailable for patients. Additionally, new immunotherapy options were approved, giving more variety and treatment options as well as post-surgery options.

[READ MORE](#)

Identification of Chemoradiation Response Mediators in Non-Small Cell Lung Cancer via Circulating Tumor DNA Analysis



Everett Moding, MD, PhD

Assistance Professor Department of Radiation Oncology, Stanford University School of Medicine

A combination of chemotherapy and radiation therapy is the backbone of treatment for non-small cell lung cancer that has spread to the lymph nodes in patients who are not candidates for surgery. Although chemoradiation therapy has the potential to be curative, most patients relapse after treatment. Furthermore, many patients are likely over-treated with higher than necessary radiation doses because there are currently no proven approaches to identify which patients could benefit from more or less treatment.

[READ MORE](#)

About Us

Founded by patients and survivors, GO2 Foundation for Lung Cancer transforms survivorship as the world's leading organization dedicated to saving, extending, and improving the lives of those vulnerable, at risk, and diagnosed with lung cancer.

DONATE TODAY!

Contact Us

Email: info@go2foundation.org | HelpLine: 1-800-298-2436 (9-5 EDT)

Washington, DC

Phone: 202-463-2080

San Francisco Bay Area

Phone: 650-598-2857

THANK YOU TO OUR SPONSORS

Genentech
A Member of the Roche Group

REGENERON | SANOFI GENZYME 

 Bristol Myers Squibb™

 **NOVARTIS**